Our Antibody-Oligonucleotide Conjugation Services support research teams developing DNA-barcoded antibodies, hybridization-enabled detection reagents, proximity assay components, multiplex imaging panels, single-cell analysis tools, and antibody-guided oligonucleotide delivery constructs. These projects combine two structurally different biomolecules: an antibody that must retain target recognition and an oligonucleotide that must remain accessible for hybridization, amplification, sequencing, or payload activity. Successful development therefore depends on more than forming a covalent bond.
Our service platform integrates construct planning, antibody and oligonucleotide preparation, conjugation chemistry selection, reaction optimization, purification, analytical characterization, and application-focused verification. Project plans are adjusted to the antibody format, oligonucleotide type, desired loading range, linker architecture, available reactive groups, downstream assay, and material scale. The resulting deliverables are designed to help customers compare candidates, understand residual risks, and move an antibody-oligo conjugate into research use with a clearer technical basis.
Fig. 1 Schematic representation of AOC use in (a) antibody arrays; (b) therapeutic; and (c) pretargeting applications. (Dovgan, 2019)
Preserving Antibody Binding: Random modification of accessible lysines or cysteines can generate broad product distributions and may place a bulky, highly charged oligonucleotide near an antigen-binding region. We assess antibody format, available handles, reduction sensitivity, conjugation site options, and target loading before selecting a route intended to reduce avoidable loss of binding performance.
Controlling Oligo Loading: Too little oligonucleotide can limit barcode signal, hybridization capacity, or payload delivery, while excessive loading can increase heterogeneity, alter solubility, and complicate purification. We optimize reactant ratios and process conditions around the intended oligonucleotide-to-antibody ratio rather than applying one loading target to every application.
Removing Mixed Species: Crude reactions may contain unconjugated antibody, free oligonucleotide, linker-modified intermediates, and conjugates carrying different oligo numbers. Because these species differ in charge, size, and hydrophobicity, a single cleanup method may be insufficient. We develop fit-for-purpose purification strategies and define which product fractions should advance.
Engineering the Oligonucleotide: Barcode orthogonality, secondary structure, terminal modification, spacer length, nuclease exposure, reporter placement, and hybridization conditions can all affect final conjugate behavior. Our oligonucleotide synthesis services and modification planning are coordinated with the conjugation route so the oligo arrives with the correct handle and application-ready architecture.
Managing Buffer Compatibility: Antibody formulations may contain amines, reducing agents, stabilizers, or carrier proteins that interfere with activation and ligation reactions. We review incoming material, perform buffer exchange where required, and select reaction conditions that balance conjugation efficiency with antibody stability and material recovery.
Connecting Chemistry to Assay Performance: Chemical confirmation alone does not show that an antibody-oligo conjugate will stain the correct target, hybridize efficiently, amplify cleanly, or produce acceptable background. We align analytical and functional checks with the planned use so project teams receive evidence that is relevant to their next experiment.
Our antibody-oligo conjugation services are organized around the decisions that most strongly affect product quality: where the oligonucleotide is attached, how many oligos are carried, which linker separates the two biomolecules, how mixed reaction species are removed, and how retained function is evaluated. Customers may provide the antibody, the oligonucleotide, or both, or request an integrated project that includes oligo synthesis and functionalization.
Projects can support individual conjugates, comparative chemistry studies, small antibody panels, and research-scale process development. Scope, analytical depth, and functional testing are defined before execution so the work package matches the intended assay or delivery study.
Conjugation chemistry should be selected according to the antibody format, available reactive groups, oligonucleotide architecture, desired loading control, and downstream assay. The matrix below summarizes common routes and the practical tradeoffs that influence project planning.
| Conjugation Route | Antibody-Side Handle | Oligo-Side Handle | Control Profile | Best-Fit Considerations | Key Tradeoffs |
| NHS-Amine Coupling | Accessible lysine amines or N-termini | Activated ester or amine-reactive linker system | Broad site distribution | Straightforward feasibility work with conventional antibody inputs | Loading heterogeneity and possible modification near binding regions |
| Thiol-Maleimide Coupling | Native, reduced, or engineered cysteine thiols | Maleimide-functionalized oligonucleotide or linker | Moderate to high, depending on thiol source | Projects requiring cysteine-selective attachment and tunable loading | Reduction conditions, thiol reoxidation, and linkage stability require review |
| SPAAC Click Ligation | Installed azide or strained alkyne handle | Complementary DBCO or azide modification | Determined by initial handle placement | Modular conjugation of separately prepared antibody and oligonucleotide partners | Handle installation and hydrophobic linker effects can influence recovery |
| IEDDA Ligation | Installed tetrazine or trans-cyclooctene handle | Complementary bioorthogonal partner | Determined by precursor design | Rapid, selective ligation when specialized handles are acceptable | Reagent stability, precursor preparation, and purification complexity |
| Fc-Glycan Conjugation | Fc-associated carbohydrate domain | Aldehyde-, aminooxy-, hydrazide-, azide-, or click-compatible oligonucleotide | Fc-biased site distribution | IgG projects seeking attachment away from the antigen-binding region | Multistep processing and dependence on glycan accessibility |
| Enzyme-Directed Coupling | Compatible peptide tag, glutamine, glycine motif, or engineered site | Enzyme-compatible oligonucleotide substrate | High site control | Engineered antibodies or fragments requiring narrow conjugate distribution | Sequence requirements, enzyme compatibility, and upstream protein engineering |
An antibody-oligonucleotide conjugate should be configured around its final readout. Barcode length, linker spacing, loading range, purity requirements, and functional tests differ substantially between sequencing, imaging, proximity, amplification, and delivery workflows.
| Research Format | Typical Oligo Configuration | Primary Design Priorities | Recommended Evaluation | Typical Deliverables |
| DNA-Barcoded Antibody Panel | Unique single-stranded DNA barcode with spacer and optional amplification handles | Barcode orthogonality, consistent loading, low free-oligo background, panel compatibility | Loading estimate, purity, binding retention, hybridization specificity, cross-panel review | Purified conjugates, barcode map, concentration data, QC summary, handling guidance |
| Single-Cell Multiomics | DNA tag containing platform-compatible capture sequence, barcode, and optional UMI structure | Sequence compatibility, antibody titration needs, background control, lot-to-lot panel consistency | Binding check, free-tag assessment, barcode accessibility, pilot staining or sequencing compatibility | Individual conjugates or panel, sequence file, QC package, recommended pilot conditions |
| Multiplex Spatial Imaging | DNA docking strand with exchange, reporter-hybridization, or cleavage-compatible design | Retained antigen recognition, spacer accessibility, reversible signal design, low nonspecific binding | Binding comparison, hybridization response, background assessment, cycle-compatibility study | Imaging-ready conjugate, imager-strand information, QC data, workflow recommendations |
| Proximity Assays | DNA arms designed for ligation, extension, or proximity-triggered hybridization | Oligo orientation, effective spacing, pair compatibility, minimal independent background | Pairwise binding, oligo accessibility, negative-control behavior, amplification response | Matched antibody-oligo pair, sequence design, conjugate QC, assay-development notes |
| Immuno-PCR and Amplified Detection | Amplifiable DNA tag with primer-binding regions and optional capture or reporter segment | PCR compatibility, low free-DNA carryover, stable attachment, target-dependent signal | Purity, amplification test, antigen binding, blank and no-target controls | Assay-ready conjugate, primer information, concentration and loading data, test summary |
| Targeted Oligo Delivery Research | siRNA, antisense oligonucleotide, steric-blocking oligo, or other modified payload | Receptor selection, internalization, payload stability, linker design, loading and solubility | Integrity, loading distribution, binding, uptake, target-dependent activity where applicable | Characterized research conjugate, analytical report, formulation notes, candidate comparison |
| Programmable Assembly | Hybridization handle for bead capture, nanostructure assembly, sensor integration, or modular labeling | Accessible sequence, controlled orientation, surface compatibility, hybridization kinetics | Binding and assembly check, hybridization response, aggregate assessment, storage compatibility | Functionalized conjugate, sequence and linker specification, QC data, assembly guidance |
Each project follows a staged workflow that connects material assessment, conjugate design, chemistry execution, purification, and functional review. Decision points are documented so customers can understand why a route was selected and which variables may require further optimization.
We confirm the intended application, antibody format, antibody source and formulation, oligonucleotide sequence or payload class, desired scale, target loading range, and required deliverables. Incoming material constraints are identified before chemistry is selected.
Candidate conjugation routes, reactive handles, linker architecture, oligo attachment site, purification strategy, and functional tests are compared. The project plan defines which variables will be fixed and which will be screened.
The antibody is buffer-exchanged or functionalized as needed, while the oligonucleotide is synthesized or prepared with the required handle, spacer, and reporter elements. Baseline quality checks help confirm that both partners are suitable for ligation.
Conjugation is executed under defined conditions. For development projects, reactant ratio, concentration, time, pH, and other relevant variables may be screened to balance conversion, material recovery, loading distribution, and product integrity.
Free oligonucleotide, unconjugated antibody, aggregates, and unwanted loading fractions are reduced using a fit-for-purpose purification workflow. The selected material is then assessed for identity, integrity, purity, loading, and other agreed attributes.
Application-relevant checks are completed, results are reviewed against the project objective, and the conjugate is delivered with sequence information, material specifications, analytical data, and handling recommendations. Follow-on optimization can focus on the variables identified during the first cycle.
Antibody-oligo projects can fail at the interfaces between protein chemistry, oligonucleotide design, purification, and assay development. Our platform is structured to manage these interfaces as one coordinated technical program rather than treating conjugation as an isolated reaction.
Antibody-oligonucleotide conjugates connect selective protein recognition with sequence-programmable nucleic acid readouts or payloads. This combination supports research workflows that need amplification, multiplexing, spatial encoding, molecular proximity, or cell-selective delivery.
Whether your program requires one antibody-DNA conjugate, a barcode panel, a matched proximity-assay pair, an imaging reagent, or an antibody-linked RNA payload, the project should begin with the intended readout and the available input materials. Share the antibody format and formulation, oligonucleotide sequence or design goal, preferred conjugation route if known, target material quantity, and required functional tests. Our team will review the technical fit, identify likely purification and characterization needs, and propose a practical work package for design, conjugation, analysis, and delivery. Contact us to discuss your antibody-oligonucleotide conjugation requirements.
Antibody-oligonucleotide conjugates (AOCs) are molecules formed by covalently linking antibodies to oligonucleotides. These conjugates are designed to target specific cells, such as cancer cells, with high precision and efficiency.
AOCs are synthesized by either covalently binding oligonucleotides to antibodies using chemical groups or non-covalently binding them through DNA/RNA hybridization techniques, depending on the desired application.
AOCs offer high specificity and selectivity, making them ideal for targeted detection or therapeutic purposes. They also reduce off-target effects, improving the accuracy of experiments and increasing the efficiency of treatments.
Key challenges in AOC research include improving drug stability, optimizing metabolism, and overcoming clearance issues. These factors need to be addressed to enhance the effectiveness and longevity of the conjugates.
Loading ......
